Chemotherapy remains a cornerstone in the treatment of many cancers, including AML, a type of blood cancer characterized by rapid proliferation of abnormal white blood cells. The variance in individual responses to treatment can often lead to suboptimal outcomes, making it critical to identify reliable biomarkers for tailoring therapies to each patient’s unique profile. In their research, Wu and colleagues shine a light on two specific proteins—ARTN and CCL23—indicating their roles in the therapeutic response of AML patients.

In essence, ARTN, or artemin, is part of the neurotrophic factor family, influencing neuronal development and function by activating specific receptors. CCL23, on the other hand, is a chemokine that plays a pivotal role in the immune response, attracting monocytes to sites of inflammation. Both proteins had not previously been linked directly to chemotherapy response, making the revelations from this study particularly significant and groundbreaking.

Utilizing Olink® proteomics, the research harnesses a highly sensitive and specific technology designed to measure multiple proteins simultaneously. This method allows for a comprehensive analysis of the proteomic landscape in AML patients, which significantly enhances the ability to detect subtle changes in protein expression that may influence chemosensitivity. The innovative application of this technique marks a critical advancement in understanding the biological underpinnings of AML.

As part of the research, the scientists conducted a thorough investigation that involved analyzing blood samples from AML patients, assessing the levels of ARTN and CCL23 before and after chemotherapy treatments. They discovered that variations in these proteins were closely correlated with the patients’ responses to chemotherapy, thereby reinforcing their potential as biomarkers for predicting treatment efficacy. This correlation is particularly important given the variability in how patients metabolize and respond to chemotherapeutic agents.

Furthermore, the findings suggest that measuring the levels of ARTN and CCL23 could significantly expedite the process of determining the most effective treatment plan for AML patients. This approach not only enhances personalized treatment strategies but also has the potential to reduce the time required to select the right therapeutic regimen, minimizing the risks associated with trial and error methods currently employed in clinical settings.

The implications of such research stretch beyond AML alone, as the integration of proteomic data into clinical practice can pave the way for more effective treatment protocols across various cancers. In an era where precision medicine is becoming increasingly pivotal, such advancements underscore the necessity of leveraging biomarker research to optimize chemotherapy outcomes and overall patient survival.

The study also draws attention to the growing importance of multi-omics approaches in cancer research. By synthesizing data from different biological layers—genomics, proteomics, and transcriptomics—researchers can establish a more intricate understanding of disease pathways, ultimately leading to better-targeted therapies. The introduction of Olink® proteomics into the investigation of AML’s response to chemotherapy exemplifies this innovative trend in medical research.

Moreover, the research team emphasizes the necessity of further studies with larger cohorts to validate these findings and expand the knowledge of these biomarkers. As science progresses, the hope is that ARTN and CCL23 could integrate into routine clinical practice, improving the predictability of chemotherapy responses and tailoring treatments based on each patient’s distinct tumor biology.

The release of these findings contributes to a sense of urgency in the scientific community to accelerate research efforts focused on tumor biomarkers. With many patients facing dire prognoses in the absence of effective therapies, the role of innovative proteomic technologies like those employed in this study cannot be overstated. Just as previous advancements in molecular biology revolutionized our understanding of cancer, the current trajectory promises to yield transformative changes to how we diagnose and treat this complex disease.

This research drives home the message that predictive biomarkers are integral to the future of oncology. As elucidated by the team led by Wu et al., the road ahead is one filled with potential. Embracing novel scientific methodologies will be crucial in delineating which patients will benefit from specific therapies, ultimately enhancing the quality of care and improving survival rates in patients afflicted with acute myeloid leukemia. Every ounce of effort invested in research today lays the groundwork for the sinews of advanced medical practices tomorrow.

In conclusion, the innovative exploration of ARTN and CCL23 as biomarkers for chemosensitivity in acute myeloid leukemia underscores the importance of advanced proteomic technologies in personalizing cancer treatments. This research not only highlights specific proteins that could help predict patient responses but also reinforces the ongoing dialogue regarding the future of tailored therapies in the realm of cancer treatment. The benefits of such work extend beyond laboratory findings, promising a brighter future for patients battling this insidious disease.

Subject of Research: Predicting chemosensitivity in acute myeloid leukemia (AML) using biomarkers.

Article Title: ARTN and CCL23 predicted chemosensitivity in acute myeloid leukemia: an Olink® proteomics approach.

Article References:

Wu, TS., Hsiao, TH., Chen, CH. et al. ARTN and CCL23 predicted chemosensitivity in acute myeloid leukemia: an Olink^® proteomics approach. Clin Proteom 22, 3 (2025). https://doi.org/10.1186/s12014-025-09527-7

Image Credits: AI Generated

DOI:

Keywords: Biomarkers, Acute Myeloid Leukemia, Chemotherapy Response, Olink Proteomics, ARTN, CCL23

Venetoclax (VEN), a potent BCL-2 inhibitor, has revolutionized AML treatment by inducing apoptosis in malignant cells, especially in patients deemed unfit for intensive chemotherapy. Azacitidine (AZA), a hypomethylating agent, complements VEN by modifying gene expression, thus facilitating leukemic cell death and reversing aberrant epigenetic alterations. Their combination has been approved in several countries for frontline AML therapy in older or frail patients but real-world data, particularly from Asian populations, have been limited until now.

The recently published retrospective cohort study at a single center in China included 50 adult AML patients treated between January 2020 and November 2023. The patient cohort comprised 29 individuals with newly diagnosed AML and 21 patients with relapsed or refractory disease, providing a comprehensive overview of VEN-AZA’s impact across the disease spectrum. The investigators employed rigorous endpoints such as overall survival (OS), composite complete remission (CR) inclusive of incomplete hematologic recovery (CRi), partial remission (PR), and event-free survival (EFS), alongside minimal residual disease (MRD) assessment and adverse event monitoring.

Among the newly diagnosed cohort, the outcomes were notably encouraging. With a median age of 74 years, reflecting a population typically ineligible for high-intensity chemotherapy, patients demonstrated a median EFS of 9.87 months and an OS nearing a full year at 11.93 months. These survival metrics underscore VEN-AZA’s capacity to deliver meaningful clinical benefit in elderly AML patients, a group historically beset by poor prognosis. Impressively, the overall response rate (ORR) reached 85.7%, with two-thirds achieving CR or CRi. MRD negativity, an emerging surrogate for deep remission and long-term survival probability, was achieved in over a quarter of this subgroup.

The study did not stop at initial responses; it explored therapeutic avenues following VEN-AZA failure, a critical but understudied phase. Post-failure treatments included combination regimens of VEN-AZA with targeted agents such as gilteritinib, chidamide, or selinexor. While these combinations yielded partial remissions or CRi, the median survival after treatment failure remained limited to 1.6 months, highlighting the urgent need for more efficacious salvage strategies. The integration of novel agents appears promising but requires further validation in robust clinical trials.

Turning to the subset with relapsed or refractory AML, median age was younger at 65 years but prognosis was poorer. Median EFS was curtailed to 5.2 months and OS to 9.1 months, reflecting the aggressive nature of disease in this context and the relative resistance to salvage therapies. Here, the ORR was lower at 52.4%, and CR/CRi was attained in just under half the patients. Furthermore, only about 11% achieved MRD negativity, indicating residual disease persistence and the challenge of overcoming chemoresistance.

Post-failure strategies in relapsed or refractory AML included induction chemotherapy, VEN-AZA combined with agents like enasidenib or gilteritinib, as well as enrollment in clinical trials evaluating novel therapies. Responses were heterogeneous, with a median post-failure OS of less than a month (0.67 months), underscoring the vulnerability of this population and the imperative to enhance salvage treatment efficacy. Adverse events were predominantly hematologic and infectious complications, consistent with the known toxicity profiles of VEN and AZA, demanding vigilant supportive care.

This study’s findings reinforce VEN-AZA’s role as a pivotal frontline treatment in AML patients who cannot tolerate conventional chemotherapy, delivering high remission rates with manageable safety concerns. The data importantly emphasize that combining VEN-AZA with targeted therapies post-failure can extend survival beyond VEN-AZA alone, suggesting that precision medicine approaches tailored to molecular mutations and disease dynamics might optimize outcomes.

Moreover, the investigation highlights the real-world complexities and heterogeneity encountered outside controlled trials, such as variations in age, disease status, and prior therapies, which can influence response rates and toxicity. These insights foster a more nuanced understanding of how VEN-AZA regimens perform in everyday clinical practice, facilitating more informed therapeutic decisions.

While encouraging, the limited sample size and single-center design necessitate cautious interpretation. The authors call for larger, multicenter studies to confirm these observations and refine predictive biomarkers for response and resistance. Optimizing dosing, sequencing, and combination partners are key areas for exploration to maximize efficacy while minimizing adverse effects.

The emergence of targeted agents such as FLT3 inhibitors (e.g., gilteritinib), IDH inhibitors (e.g., enasidenib), and epigenetic modulators offer fertile ground for combinatorial regimens with VEN-AZA, potentially transforming the treatment paradigm in relapsed or refractory AML. Furthermore, MRD monitoring may guide treatment intensity and duration, identifying patients who might benefit from consolidation or allogeneic stem cell transplant.

In terms of safety, the study confirmed that hematologic toxicity and infections remain the most common adverse events but are generally manageable with contemporary supportive care measures. These findings highlight the importance of infection prophylaxis and close monitoring, particularly given the immunosuppressive effects inherent to AML and its treatment.

Overall, this real-world data enriches the evolving landscape of AML therapeutics by validating VEN-AZA’s efficacy and safety in a Chinese population, extending understanding beyond prior Western-centric clinical trials. It also underscores the limitations faced once VEN-AZA fails, underscoring a critical need for novel agents and strategic sequencing to overcome resistance and prolong survival.

The insights gained could accelerate the adoption of VEN-AZA-based regimens in diverse clinical settings globally while inspiring further research into combinatorial strategies that harness targeted therapy synergy. This progress brings hope to patients with AML, particularly older adults and those with limited treatment options, moving the field toward more personalized and effective interventions against a devastating disease.

As the fight against acute myeloid leukemia advances, integrating real-world evidence with translational research and emerging therapies is paramount. This study stands as a testament to the potential of VEN-AZA combination therapy and the imperative to innovate continuously in the quest to improve patient outcomes in AML.

Subject of Research: Efficacy and safety of venetoclax and azacitidine combination therapy in patients with acute myeloid leukemia, including outcomes post-therapy failure.

Article Title: Efficacy and safety of venetoclax and azacitidine for acute myeloid leukemia in China: a real-world single-center study.

Article References:
Bai, JF., Wang, T., Li, JT. et al. Efficacy and safety of venetoclax and azacitidine for acute myeloid leukemia in China: a real-world single-center study.
BMC Cancer 25, 990 (2025). https://doi.org/10.1186/s12885-025-14167-z

Image Credits: Scienmag.com

DOI: https://doi.org/10.1186/s12885-025-14167-z